# Effectiveness and Safety of Nexpowder as an Endoscopic Hemostatic Treatment

> **NCT05884931** · NA · COMPLETED · sponsor: **Next Biomedical Co., Ltd.** · enrollment: 66 (actual)

## Conditions studied

- GastroIntestinal Bleeding

## Interventions

- **DEVICE:** Nexpowder
- **PROCEDURE:** Conventional Treatment

## Key facts

- **NCT ID:** NCT05884931
- **Lead sponsor:** Next Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-18
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-29
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05884931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05884931, "Effectiveness and Safety of Nexpowder as an Endoscopic Hemostatic Treatment". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05884931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*